Tuberculosis is one of the most dangerous infectious diseases on the planet. In 2023, it reclaimed its position as the world’s leading infectious disease killer, surpassing COVID-19. What makes TB particularly severe is not just its ability to kill, but the lasting damage it inflicts on the lungs and other organs, even in people who survive and complete treatment.
Not Everyone With TB Gets Sick
One of the most important things to understand about tuberculosis is that infection and disease are not the same thing. Most people who breathe in the bacteria don’t immediately become ill. Instead, their immune system walls off the bacteria, creating a state called latent TB. In this phase, you have no symptoms, can’t spread the infection, and may never know you were exposed.
About 10% of people with normal immune systems who have latent TB will eventually develop active disease at some point in their lives, with the highest risk coming in the first two years after infection (roughly 5% of lifetime risk falls in that window). But certain conditions dramatically change those odds. People with diabetes face about a 30% lifetime risk of progression. People living with untreated HIV face 7% to 10% risk per year, which compounds to near-certainty over time.
When latent TB does become active, it shifts from a contained, silent infection into a destructive disease that eats through lung tissue and, without treatment, kills roughly half the people it affects.
What TB Does to Your Lungs
The damage TB causes is not subtle. When the bacteria begin multiplying in lung tissue, your immune system mounts an aggressive response, forming dense clusters of immune cells called granulomas around the infected areas. These granulomas surround a core of dead, cheese-like tissue where the bacteria are concentrated. The structures are meant to contain the infection, but they come at a cost: the lung tissue inside and around them is destroyed in the process.
As the disease progresses, these dead tissue centers can liquefy and break apart. When you cough, the liquefied material is expelled, leaving behind gas-filled holes in the lung called cavities. This cavitation process destroys the normal architecture of the lung, wiping out the tiny air sacs where oxygen exchange happens, along with the blood vessels and airways running through those areas. It’s also what makes TB so contagious: coughing up liquefied cavity contents sprays bacteria into the air.
Even as the body tries to heal, the repair process often goes wrong. Excessive scar tissue (fibrosis) replaces normal lung tissue, thickening and stiffening the lung walls. The airways themselves can become permanently widened and damaged, a condition called bronchiectasis, caused by a combination of scarring, tissue destruction, and the sheer force of chronic coughing. A family of enzymes that break down structural tissue play a central role in this remodeling, essentially dissolving the scaffolding that holds lung architecture together.
TB Can Spread Beyond the Lungs
While the lungs are the primary target, TB bacteria can travel through the bloodstream to virtually any organ. The most common sites outside the lungs include lymph nodes, the lining around the lungs, the abdomen, the urinary and reproductive tracts, skin, joints, bones, and the membranes surrounding the brain.
Spinal TB, historically known as Pott’s disease, is one of the more devastating forms. The bacteria infect the vertebrae and the discs between them, potentially causing spinal cord compression, nerve damage, and in severe cases, paralysis. TB in the brain and its surrounding membranes (tuberculous meningitis) is the most lethal form, often causing permanent neurological damage even with treatment. These extrapulmonary forms can be harder to diagnose because symptoms mimic many other conditions, and standard tests designed for lung TB may miss them entirely.
Lung Damage That Outlasts the Disease
One of the least discussed aspects of TB is what happens after successful treatment. Even when every last bacterium is cleared, the structural damage to the lungs often persists. In a study of 145 people who had completed TB treatment and were considered cured, 38% had measurable airflow obstruction and 58% had reduced lung capacity. On average, participants had lost about a quarter of their expected lung function, with some losing far more.
The symptoms reflect that damage. Among these cured patients, 42% experienced wheezing, 25% had significant breathlessness during daily activities, and 19% had a chronic cough that never went away. Despite these ongoing problems, only 13% had received a formal diagnosis of a respiratory condition, and just 11% were using inhalers. Post-TB lung disease is, in many cases, a chronic condition that goes unrecognized and untreated.
Treatment Works, but It’s Long and Demanding
Standard TB is curable with antibiotics, but treatment requires a level of commitment that surprises most people. The regimen lasts 4 to 9 months depending on the specific drug combination, broken into an intensive phase of about 2 months followed by a continuation phase of 2 to 7 additional months. Missing doses or stopping early doesn’t just risk relapse. It creates the conditions for the bacteria to develop drug resistance, turning a treatable disease into something far more dangerous.
Drug-resistant TB is where the picture gets genuinely grim. When the bacteria evolve to resist the two most powerful first-line drugs, the condition is classified as multidrug-resistant TB (MDR-TB). Treatment for MDR-TB is longer, more expensive (over $1,000 per person even in low-cost settings), and causes significantly more side effects. The global treatment success rate for MDR-TB sits at 63%, meaning more than a third of patients either die, fail treatment, or are lost to follow-up. That’s improved from 50% a decade ago, but it still represents a disease with a poor prognosis when resistance develops.
Diagnosis Has Improved, but Gaps Remain
How quickly TB is caught makes an enormous difference in outcomes. The traditional method of examining sputum (coughed-up mucus) under a microscope is cheap and fast, delivering results in under an hour, but it catches only about 58% to 68% of true cases when compared against the gold standard of bacterial culture, which takes 6 to 8 weeks to produce results.
Rapid molecular testing has closed much of that gap. These cartridge-based tests identify TB bacteria and simultaneously check for resistance to a key antibiotic, all within about 2 hours. In head-to-head comparisons, molecular testing detected 97.4% of confirmed TB cases versus 86.2% for microscopy. In practical terms, using the molecular test identified an additional 15.6% of confirmed cases that microscopy alone would have missed. That matters because every missed diagnosis means weeks or months of ongoing lung destruction and continued transmission to others.
Who Faces the Greatest Risk
TB hits hardest where immune systems are weakened. HIV co-infection is the single biggest risk factor for progressing from latent infection to active disease, but diabetes, malnutrition, smoking, heavy alcohol use, and immunosuppressive medications all raise the stakes substantially. People living in crowded conditions, including prisons, shelters, and dense urban housing, face higher exposure risk simply because TB spreads through the air in enclosed spaces.
Age matters too. Young children and older adults are more likely to develop severe forms of the disease, including the extrapulmonary types that affect the brain and spine. For children under five, TB can progress rapidly from infection to life-threatening illness in a matter of weeks, compared to the months or years it typically takes in healthy adults.